The worldwide obesity crisis has become a dominant public health crisis across the globe. Over 3 billion people worldwide currently suffer from obesity, and forecasts warn the number will rise above 4 billion by 2035, accounting for more than half the global population. As a major non-communicable disease, obesity triggers persistent visceral adipose inflammation and drastically raises risks of type 2 diabetes, cardiovascular illnesses, metabolic fatty liver disease and various cancers.
Semaglutide, a mainstream GLP-1 agonist approved for weight loss, suppresses appetite by activating central hypothalamic GLP-1 receptors to regulate systemic energy balance. Despite its reliable weight-lowering performance, the drug's brain-centered mechanism leads to rapid weight regain once treatment stops, which severely limits long-term metabolic benefits. Researchers have attempted to pair semaglutide with adipose-targeted browning compounds to boost fat energy consumption, yet chronic inflammatory adipose microenvironments block thermogenic gene expression and weaken such therapeutic effects.
New research reveals an overlooked peripheral immunomodulatory property of semaglutide. Apart from its central appetite-regulating function, semaglutide binds GLP-1 receptors on adipose macrophages and drives their shift from pro-inflammatory M1 to anti-inflammatory M2 subtypes, easing local adipose inflammation. This finding inspired the team to design a synergistic dual-drug therapy pairing semaglutide with rosiglitazone, a PPAR-γ agonist that stimulates white fat browning.
